Title: Evaluation of the causal effects of blood metabolites on irritable bowel syndrome:
Mendelian randomization
Version: 0 Date: 14 Nov 2023
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
Manuscript highlights new possible biomarkers in IBS. These findings are essential in clinical
practice and are worthy of publication in scientific journals. Some minor revision suggested:
1. Expand the clinical use of omics technologies in the introduction. The paper doi: 10.3389/
fcimb.2022.1010979 should be cited.
2. Clarify in the methods how the diagnosis of IBS was made.
3. What are the future perspectives?
Title: Evaluation of the causal effects of blood metabolites on irritable bowel syndrome:
Mendelian randomization
Version: 0 Date: 14 Nov 2023
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
Manuscript highlights new possible biomarkers in IBS. These findings are essential in clinical
practice and are worthy of publication in scientific journals. Some minor revision suggested:
1. Expand the clinical use of omics technologies in the introduction. The paper doi: 10.3389/
fcimb.2022.1010979 should be cited.
2. Clarify in the methods how the diagnosis of IBS was made.
3. What are the future perspectives?
Please review this paper.
user
Title: Evaluation of the causal effects of blood metabolites on irritable bowel syndrome:
Mendelian randomization
Version: 0 Date: 14 Nov 2023
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
Manuscript highlights new possible biomarkers in IBS. These findings are essential in clinical
practice and are worthy of publication in scientific journals. Some minor revision suggested:
1. Expand the clinical use of omics technologies in the introduction. The paper doi: 10.3389/
fcimb.2022.1010979 should be cited.
2. Clarify in the methods how the diagnosis of IBS was made.
3. What are the future perspectives?
assistant